COMMITMENTS AND CONTINGENCIES (Tables)

6 Months Ended

Jun. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

Schedule of Contingent Consideration

A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the six months ended June 30, 2020 and June 30, 2019 is as follows (in thousands):

Six Months Ended June 30, 2020	Contingent Consideration Liability Related to Acquisition of Arkis (See Note 2)			Contingent Consideration  Liability Related to Acquisition of Derma Sciences		Location in Financial Statements
	Long-term			Long-term
Balance as of January 1, 2020	$	14,210		$	230
Payments	—			—
Loss from change in fair value of contingent consideration liabilities	(708		)	—		Research and development
Balance as of June 30, 2020	$	13,502		$	230

Six Months Ended June 30, 2019	Contingent Consideration  Liability Related to Acquisition of Derma Sciences
	Long-term
Balance as of January 1, 2019	$	230
Payments	—
Loss from change in fair value of contingent consideration liabilities	—
Balance as of June 30, 2019	$	230